Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-004896
Filing Date
2023-02-14
Accepted
2023-02-14 16:16:07
Documents
84
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1067708
2 ex31-1.htm EX-31.1 19756
3 ex31-2.htm EX-31.2 18781
4 ex32-1.htm EX-32.1 7610
5 ex32-2.htm EX-32.2 7488
  Complete submission text file 0001493152-23-004896.txt   6095370

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE eltp-20221231.xsd EX-101.SCH 48048
7 XBRL CALCULATION FILE eltp-20221231_cal.xml EX-101.CAL 74185
8 XBRL DEFINITION FILE eltp-20221231_def.xml EX-101.DEF 186291
9 XBRL LABEL FILE eltp-20221231_lab.xml EX-101.LAB 390634
10 XBRL PRESENTATION FILE eltp-20221231_pre.xml EX-101.PRE 317155
78 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 960331
Mailing Address 165 LUDLOW AVENUE NORTHVALE NJ 07647
Business Address 165 LUDLOW AVENUE NORTHVALE NJ 07647 2017502646
ELITE PHARMACEUTICALS INC /NV/ (Filer) CIK: 0001053369 (see all company filings)

EIN.: 223542636 | State of Incorp.: NJ | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-15697 | Film No.: 23629537
SIC: 2834 Pharmaceutical Preparations